Annual CFO
-$193.31 M
-$78.01 M-67.66%
December 31, 2023
Summary
- As of February 7, 2025, INBX annual cash flow from operations is -$193.31 million, with the most recent change of -$78.01 million (-67.66%) on December 31, 2023.
- During the last 3 years, INBX annual CFO has fallen by -$145.34 million (-303.00%).
- INBX annual CFO is now -930.87% below its all-time high of -$18.75 million, reached on December 31, 2017.
Performance
INBX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$30.28 M
+$49.81 M+62.19%
September 30, 2024
Summary
- As of February 7, 2025, INBX quarterly cash flow from operations is -$30.28 million, with the most recent change of +$49.81 million (+62.19%) on September 30, 2024.
- Over the past year, INBX quarterly CFO has increased by +$49.81 million (+62.19%).
- INBX quarterly CFO is now -504.77% below its all-time high of $7.48 million, reached on December 31, 2023.
Performance
INBX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$143.21 M
+$23.96 M+14.33%
September 30, 2024
Summary
- As of February 7, 2025, INBX TTM cash flow from operations is -$143.21 million, with the most recent change of +$23.96 million (+14.33%) on September 30, 2024.
- Over the past year, INBX TTM CFO has increased by +$23.96 million (+14.33%).
- INBX TTM CFO is now -6674.27% below its all-time high of -$2.11 million, reached on March 31, 2018.
Performance
INBX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
INBX Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -67.7% | +62.2% | +14.3% |
| 3 y3 years | -303.0% | -12.4% | -24.2% |
| 5 y5 years | -737.1% | -12.4% | -24.2% |
INBX Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -140.7% | at low | -504.8% | +62.2% | -78.3% | +14.3% |
| 5 y | 5-year | -502.6% | at low | -504.8% | +62.2% | -355.9% | +14.3% |
| alltime | all time | -930.9% | at low | -504.8% | +62.2% | -6674.3% | +14.3% |
Inhibrx Biosciences Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$30.28 M(-62.2%) | -$143.21 M(-14.3%) |
| Jun 2024 | - | -$80.09 M(+98.7%) | -$167.17 M(+17.4%) |
| Mar 2024 | - | -$40.31 M(-638.9%) | -$142.38 M(+10.4%) |
| Dec 2023 | -$193.31 M(+67.7%) | $7.48 M(-113.8%) | -$129.01 M(-22.8%) |
| Sep 2023 | - | -$54.24 M(-1.9%) | -$167.09 M(+16.3%) |
| Jun 2023 | - | -$55.30 M(+105.3%) | -$143.68 M(+24.6%) |
| Mar 2023 | - | -$26.94 M(-12.0%) | -$115.30 M(-0.0%) |
| Dec 2022 | -$115.30 M(+43.5%) | -$30.60 M(-0.8%) | -$115.30 M(+7.4%) |
| Sep 2022 | - | -$30.84 M(+14.5%) | -$107.32 M(+19.0%) |
| Jun 2022 | - | -$26.92 M(-0.1%) | -$90.16 M(+5.3%) |
| Mar 2022 | - | -$26.94 M(+19.1%) | -$85.62 M(+6.6%) |
| Dec 2021 | -$80.32 M | -$22.62 M(+65.4%) | -$80.32 M(+9.9%) |
| Sep 2021 | - | -$13.68 M(-38.9%) | -$73.09 M(-0.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2021 | - | -$22.38 M(+3.4%) | -$73.30 M(+17.8%) |
| Mar 2021 | - | -$21.65 M(+40.7%) | -$62.23 M(+29.7%) |
| Dec 2020 | -$47.97 M(+49.5%) | -$15.39 M(+10.9%) | -$47.97 M(+7.7%) |
| Sep 2020 | - | -$13.88 M(+22.8%) | -$44.52 M(+41.7%) |
| Jun 2020 | - | -$11.31 M(+53.1%) | -$31.41 M(-7.3%) |
| Mar 2020 | - | -$7.39 M(-38.1%) | -$33.89 M(+5.6%) |
| Dec 2019 | -$32.08 M(+38.9%) | -$11.94 M(+1444.9%) | -$32.08 M(+59.3%) |
| Sep 2019 | - | -$773.00 K(-94.4%) | -$20.14 M(+4.0%) |
| Jun 2019 | - | -$13.79 M(+147.2%) | -$19.36 M(+4.2%) |
| Mar 2019 | - | -$5.58 M(-57.1%) | -$18.58 M(+22.9%) |
| Dec 2018 | -$23.09 M(+23.1%) | - | - |
| Jun 2018 | - | -$13.01 M(+515.3%) | -$15.12 M(+615.3%) |
| Mar 2018 | - | -$2.11 M | -$2.11 M |
| Dec 2017 | -$18.75 M | - | - |
FAQ
- What is Inhibrx Biosciences annual cash flow from operations?
- What is the all time high annual CFO for Inhibrx Biosciences?
- What is Inhibrx Biosciences annual CFO year-on-year change?
- What is Inhibrx Biosciences quarterly cash flow from operations?
- What is the all time high quarterly CFO for Inhibrx Biosciences?
- What is Inhibrx Biosciences quarterly CFO year-on-year change?
- What is Inhibrx Biosciences TTM cash flow from operations?
- What is the all time high TTM CFO for Inhibrx Biosciences?
- What is Inhibrx Biosciences TTM CFO year-on-year change?
What is Inhibrx Biosciences annual cash flow from operations?
The current annual CFO of INBX is -$193.31 M
What is the all time high annual CFO for Inhibrx Biosciences?
Inhibrx Biosciences all-time high annual cash flow from operations is -$18.75 M
What is Inhibrx Biosciences annual CFO year-on-year change?
Over the past year, INBX annual cash flow from operations has changed by -$78.01 M (-67.66%)
What is Inhibrx Biosciences quarterly cash flow from operations?
The current quarterly CFO of INBX is -$30.28 M
What is the all time high quarterly CFO for Inhibrx Biosciences?
Inhibrx Biosciences all-time high quarterly cash flow from operations is $7.48 M
What is Inhibrx Biosciences quarterly CFO year-on-year change?
Over the past year, INBX quarterly cash flow from operations has changed by +$49.81 M (+62.19%)
What is Inhibrx Biosciences TTM cash flow from operations?
The current TTM CFO of INBX is -$143.21 M
What is the all time high TTM CFO for Inhibrx Biosciences?
Inhibrx Biosciences all-time high TTM cash flow from operations is -$2.11 M
What is Inhibrx Biosciences TTM CFO year-on-year change?
Over the past year, INBX TTM cash flow from operations has changed by +$23.96 M (+14.33%)